NRx Pharmaceuticals (NASDAQ:NRXP) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of NRx Pharmaceuticals (NASDAQ:NRXP) from a hold rating to a sell rating in a report issued on Saturday.

NRXP has been the topic of a number of other research reports. BTIG Research dropped their price target on NRx Pharmaceuticals to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. D. Boral Capital reaffirmed a “buy” rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday, May 5th. Ascendiant Capital Markets upped their price objective on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a report on Monday, April 27th. HC Wainwright reissued a “buy” rating on shares of NRx Pharmaceuticals in a research report on Monday, August 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 5th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.50.

NRx Pharmaceuticals Stock Up 4.9%

NASDAQ:NRXP opened at $3.43 on Friday. The stock’s 50 day moving average price is $3.78 and its two-hundred day moving average price is $2.97. The firm has a market capitalization of $124.27 million, a price-to-earnings ratio of -6.24 and a beta of 2.18. NRx Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $5.05.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The firm had revenue of $1.10 million during the quarter, compared to the consensus estimate of $1.33 million. Equities research analysts expect that NRx Pharmaceuticals will post -0.3 EPS for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Ethos Financial Group LLC lifted its holdings in NRx Pharmaceuticals by 33.6% during the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after purchasing an additional 4,000 shares during the last quarter. State Street Corp grew its holdings in NRx Pharmaceuticals by 14.0% in the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after buying an additional 10,700 shares in the last quarter. Two Sigma Investments LP grew its holdings in NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after buying an additional 20,880 shares in the last quarter. Geode Capital Management LLC grew its holdings in NRx Pharmaceuticals by 17.8% in the 4th quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock valued at $593,000 after buying an additional 33,004 shares in the last quarter. Finally, Global Retirement Partners LLC bought a new position in NRx Pharmaceuticals during the 4th quarter worth $107,000. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.